Home/Filings/4/0000950170-24-028827
4//SEC Filing

Tourangeau Greg 4

Accession 0000950170-24-028827

CIK 0001680581other

Filed

Mar 7, 7:00 PM ET

Accepted

Mar 8, 6:05 PM ET

Size

5.1 KB

Accession

0000950170-24-028827

Insider Transaction Report

Form 4
Period: 2024-03-08
Tourangeau Greg
Principal Accounting Officer
Transactions
  • Sale

    Common Stock

    2024-03-08$11.72/sh4,884$57,21911,807 total
Footnotes (2)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.71 to $11.74, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
  • [F2]Includes 699 shares acquired under the Issuer's employee stock purchase plan on May 13, 2022.

Documents

1 file

Issuer

Fulcrum Therapeutics, Inc.

CIK 0001680581

Entity typeother

Related Parties

1
  • filerCIK 0001916566

Filing Metadata

Form type
4
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 6:05 PM ET
Size
5.1 KB